Immunome, Inc. $IMNM Stock Bought by Alps Advisors Inc.

Alps Advisors Inc. lifted its position in shares of Immunome, Inc. (NASDAQ:IMNM) by 31.5% during the third quarter, Holdings Channel.com reports. The firm owned 150,502 shares of the company’s stock after purchasing an additional 36,062 shares during the period. Alps Advisors Inc.’s holdings in Immunome were worth $3,237,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of IMNM. BlackRock Inc. purchased a new stake in shares of Immunome in the second quarter worth approximately $186,588,000. Wellington Management Group LLP grew its position in Immunome by 10.1% during the second quarter. Wellington Management Group LLP now owns 5,210,216 shares of the company’s stock valued at $110,404,000 after buying an additional 478,239 shares during the period. Primecap Management Co. CA purchased a new stake in Immunome during the second quarter worth about $97,081,000. Readystate Asset Management LP raised its position in Immunome by 23.3% in the second quarter. Readystate Asset Management LP now owns 1,605,820 shares of the company’s stock worth $34,027,000 after acquiring an additional 303,958 shares during the period. Finally, Bank of America Corp DE boosted its stake in Immunome by 285.6% in the first quarter. Bank of America Corp DE now owns 781,607 shares of the company’s stock valued at $17,094,000 after acquiring an additional 578,890 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Insider Buying and Selling at Immunome

In related news, Director Isaac Barchas sold 11,048 shares of Immunome stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total transaction of $301,058.00. Following the completion of the sale, the director owned 92,211 shares of the company’s stock, valued at approximately $2,512,749.75. This trade represents a 10.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 13,200 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the transaction, the insider owned 65,050 shares of the company’s stock, valued at approximately $1,647,066. The trade was a 16.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 7.21% of the company’s stock.

Immunome Stock Up 3.5%

Shares of IMNM opened at $19.36 on Tuesday. The business’s 50-day moving average price is $21.33 and its 200-day moving average price is $22.37. Immunome, Inc. has a twelve month low of $15.46 and a twelve month high of $30.06. The stock has a market cap of $2.20 billion, a PE ratio of -7.65 and a beta of 2.68.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, November 10th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.15). Analysts expect that Immunome, Inc. will post -2.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on IMNM shares. Alliance Global Partners initiated coverage on shares of Immunome in a research report on Monday, September 21st. They set a “buy” rating and a $32.00 target price for the company. Truist Financial lifted their price target on shares of Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Thursday, October 15th. Wall Street Zen lowered shares of Immunome from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th. Finally, HC Wainwright reissued a “buy” rating on shares of Immunome in a research report on Tuesday, October 27th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $34.25.

Immunome Company Profile

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need.

The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.

Immunome became a publicly traded company in 2023 following a merger with Morphimmune and a combination with Ayala Pharmaceuticals.